ANI Pharmaceuticals - Jobs & Pipeline

INDERAL LA

propranolol hydrochloride

LOE Approaching

ORAL · CAPSULE, EXTENDED RELEASE

CLINICAL PHARMACOLOGY General Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. When access to beta-receptor sites is blocked by propranolol, the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain. Inderal LA should not be considered a simple mg-for-mg substitute for conventional propranolol and the blood levels achieved do not match (are lower than) those of two to four times daily dosing with the same dose (see ). When changing to Inderal LA from conventional propranolol, a possible need for retitration upwards should be considered, especially to maintain effectiveness at the end of the dosing interval. In most clinical settings, however, such as hypertension or angina where there is little correlation between plasma levels and clinical effect, Inderal LA has been therapeutically equivalent to the same mg dose of conventional Inderal as assessed by 24-hour effects on blood pressure and on 24-hour exercise responses of heart rate, systolic pressure, and rate pressure product. Mechanism of Action The mechanism of the antihypertensive effect of propranolol has not been established. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action which affects the cardiac action p

1983

$8M Part D

Pipeline & Clinical Trials

Iluvien Registry Safety Study

Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies

N/A

Clinical Trials (1)

NCT01998412Iluvien Registry Safety Study

N/A

Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Av

Diabetic Macular Edema (DME)

N/A

Clinical Trials (1)

NCT02080091Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies

N/A

Yutiq 0.18 MG Drug Implant

Uveitis

Phase 3

Clinical Trials (1)

NCT05486468The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

Phase 3

ILUVIEN

Chronic Diabetic Macular Edema

Phase 4

Clinical Trials (1)

NCT02472366A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy

Phase 4

Iluvien 0.19 MG Drug Implant

Diabetic Macular Edema

Phase 4

Clinical Trials (1)

NCT04469595A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Phase 4

fluocinolone acetonide

Diabetic Macular Edema

Phase 4

Clinical Trials (5)

NCT05322070Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Phase 4

NCT06539481Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.

corticotropin

Gout

Phase 4

Purified Cortophin Gel, 40 U

Gout Arthritis

Phase 4

Clinical Trials (1)

NCT07346079Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

Phase 4

fluocinolone acetonide

Non-infectious Posterior Segment Uveitis

Phase 4

ILUVIEN 0.19 MG

Diabetic Macular Edema (DME)

Phase 4

Clinical Trials (1)

NCT02424019Phase 4 IOP Signals Associated With ILUVIEN®

Phase 4

ANI Pharmaceuticals(ANIP)

About ANI Pharmaceuticals

Key Products

Products & Portfolio (62)

Key Products by Revenue

Other Products (51)

Pipeline & Clinical Trials

Recent News · ANI Pharmaceuticals(10)

Open Jobs (0)

Financials (FY2025)

Research Publications(4)